Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

Matt E. Kalaycio, Manisha Kukreja, Ann E. Woolfrey, Jeffrey Szer, Jorge Cortes, Richard T. Maziarz, Brian J. Bolwell, Andreas Buser, Edward Copelan, Robert Peter Gale, Vikas Gupta, Dipnarine Maharaj, David I. Marks, Steven Z. Pavletic, Mary M. Horowitz, Mukta Arora

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Issue number4
StatePublished - Apr 2010
Externally publishedYes


  • Allogeneic stem cell transplantation
  • Prolymphocytic leukemia

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia'. Together they form a unique fingerprint.

Cite this